MedDataX Logo

Gut Hormones After Oral Versus Intravenous Amino Acids

NCT ID: NCT01366768

Last Updated: 2012-10-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study hypothesis is that gut hormones are released after oral but not intravenous amino acids which result in stimulation of insulin secretion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Amino acid mixture is given orally or intravenously to match total concentrations of amino acids in healthy subjects. Samples are taken regularly for 300 min after administrations. Plasma levels of the gut hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)and determined and related to plasma levels of insulin and glucagon.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Normal Non-fluency

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Gut hormones Insulin secretion Normal physiology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral amino acid mixture

Oral administration of amino acid mixture in healthy volunteers

Group Type EXPERIMENTAL

Oral amino acid mixture

Intervention Type OTHER

Amino acid mixture 2,93 ml/kg

Intravenous amino acid administration

Intravenous infusion of amino acid mixture in healthy volunteers

Group Type EXPERIMENTAL

Intravenous amino acid administration

Intervention Type OTHER

Amino acid mixture 2,93 ml/kg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral amino acid mixture

Amino acid mixture 2,93 ml/kg

Intervention Type OTHER

Intravenous amino acid administration

Amino acid mixture 2,93 ml/kg

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Amino acid mixture Amino acid mixture

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subjects

Exclusion Criteria

* Diabetes
* Liver disease
* Kidney disease
* Thyroid disease
Minimum Eligible Age

20 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lund University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bo Ahren

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bo Ahrén, PhD

Role: PRINCIPAL_INVESTIGATOR

Lund University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Clinical Sciences Lund, Lund University

Lund, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

003

Identifier Type: -

Identifier Source: org_study_id